The estrogen component of OCs: Cardiovascular benefits and risks

International Journal of Fertility and Women's Medicine

Volumn 42, Issue SUPPL. 1, 1997, Pages 145-157

  Burkman, Ronald T ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Estrogen; Myocardial infarction; Oral contraceptives; Smoking; Stroke; Venous thromboembolism

Indexed keywords

CARBOHYDRATE; ESTROGEN; GESTAGEN; LIPID; LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; PROTEIN;

ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR EFFECT; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG FORMULATION; FEMALE; HEART INFARCTION; HEMOSTASIS; HUMAN; LIPID METABOLISM; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; ADULT; CHEMICALLY INDUCED DISORDER; SMOKING; VASCULAR DISEASE;

ADULT; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; FEMALE; HUMANS; MYOCARDIAL INFARCTION; SMOKING; VASCULAR DISEASES;

EID: 0031414812     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Mishell DR, Jr: Oral contraception: past, present, and future perspectives. Int J Fertil 36(Suppl):7-18, 1991.
2. Lobo RA, Stanczyk FZ: New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 170;1499-1507, 1994.
3. Speroff L, Darney PD: A Clinical Guide for Contraception. 2nd ed. Baltimore, William & Wilkins, pp 25-117, 1996.
4. Royal College of General Practitioners: Oral contraception and thromboembolic disease. J Coll Gen Practit 13:267-279, 1967.
5. Inman WHW, Vessey MP, Westerholm B, Engelund A: Thromboembolic disease and steroidal content of oral contraceptives: a report to the Committe on Safety of Drugs. Br Med J 2:203-209, 1970.
6. Royal College of General Practitioners: Oral Contraceptives and Health: An Interim Report. London, Pitman, 1974.
7. Wessler S: Estrogen-associated thromboembolism. Ann Epidemiol 2:439-443, 1992.
8. Meade TW, Haines AP, North WRS, et al: Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen. Lancet ii:948-951, 1977.
9. Samsioe G: Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 170:1523-1527, 1994.
10. Norris LA, Bonnar J: The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol 103:261-267, 1996.
11. Daume E: Influence of modern low-dose oral contraceptives on hemostatis. Adv Contracep 6(Suppl):51-68, 1990.
12. Deslypere JP, Thiery M, Vermculen A: Effect of long-term hormonal contraception on plasma lipids. Contraception 31:633-642, 1985.
13. Krauss RM, Burkman RT, Jr: The metabolic impact of oral contraceptives. Am J Obstet Gynecol 167:1177-1184, 1992.
14. Speroff L, DeCherney A, The Advisory Board for the New Progestins: Evaluation of a new generation of oral contraceptives. Obstet Gynecol 81:1034-1047, 1993.
15. Kjos SL, Shoupe D, Douyan S, et al: Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized prospective study. Am J Obstet Gynecol 163:1822-1827, 1990.
16. Slone E, Shapiro S, Kaufman DW, et al: Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 305:420-424, 1981.
17. Engel H-J, Engel E, Lichtlen PR: Coronary atherosclerosis and myocardial infarction in young women - role of oral contraceptives. Eur Heart J 4:1-8, 1983.
18. Stampfer MJ, Willett WC, Colditz GA, et al: A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 319:1313-1317, 1988.
19. Stampfer MJ, Willett WC, Colditz GA, et al: Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 163:285-291, 1990.
20. Adams MR, Clarkson TB, Koritnik DR, et al: Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 47:1010-1018, 1987.
21. Wagner JD, Clarkson TB, St. Clair RW, et al: Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 88:1995-2002, 1991.
22. Williams JK, Adams MR, Klopfenstein HS: Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 81:1680-1687, 1990.
23. Mann JI: Progestogens in cardiovascular disease: an introduction to the epidemiologic data. Am J Obstet Gynecol 142:752-757, 1982.
24. Meade TW, Greenberg G, Thompson SG: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations. Br Med J 280:1157-1161, 1980.
25. Vandenbroucke JP, Koster T, Briët E, et al: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344:1453-1457, 1994.
26. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease in combined oral contraceptives: results of an international multicentre case control study. Lancet 346:1575-1582, 1995.
27. Spitzer WO, Lewis MA, Heinemann LAJ, et al on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 312:83-88, 1996.
28. Farmer RDT, Preston TD: The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynecol 15:195-200, 1995.
29. Gerstman BB, Piper JM, Tomita DK, et al: Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133:32-37, 1991.
30. Vessey MP, Lawless M, Yeates D: Oral contraceptives and stroke: findings in a large prospective study. Br Med J 289:530-531, 1984.
31. Lidegaard Ø: Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J 306:956-963, 1993.
32. Hannaford PC, Croft PR, Kay CR: Oral contraception and stroke: evidence from the Royal College of General Practitioners' Oral Contraception Study. Stroke 25:935-942, 1994.
33. Petitti DB, Sidney S, Bernstein A, et al: Stroke in users of low-dose oral contraceptives. N Engl J Med 335:8-15, 1996.
34. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 348:498-505, 1996.
35. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 348:505-510, 1996.
36. American Heart Association: Heart and Stroke Facts: 1996 Statistical Supplement. National Center, Dallas, Texas.
37. Rich-Edwards JW, Manson JE, Hennekens CH, et al: The primary prevention of coronary heart disease in women. N Engl J Med 332:1758-1766, 1995.
38. Croft P, Hannaford PC: Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. Br Med J 298:165-168, 1989.
39. Harlap S, Kost K, Forrest JD: Preventing Pregnancy, Protecting Health: A New Look at Birth Control Choices in the United States. New York, The Alan Guttmacher Institute, 1991.
40. Rosenberg L, Palmer JR, Lesko SM, et al: Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 131:1009-1016, 1990.
41. Thorogood M, Mann J, Murphy M, et al: Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-con- trol study. Br J Obstet Gynaecol 98:1245-1253, 1991.
42. Mileikowsky GN, Nadler JL, Huey F, et al: Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives. Am J Obstet Gynecol 159:1547-1552, 1988.
43. 2 and prostacyclin metabolites in women stratified by age. Circulation 86:1495-1500, 1992.
44. Royal College of General Practitioners' Oral Contraceptive Study: Further analyses of mortality in oral contraceptive users. Lancet i:541-546, 1981.
45. Vessey MP, McPherson K, Yeates D: Mortality in oral contraceptive users. Lancet i:549-551, 1981.
46. Flint PM, Lapane KL, Barbour MM, et al: Cardiovascular risk profiles of oral contraceptive users and nonusers: a population-based study. Prev Med 24:586-590, 1995.
47. Castelli WP, Conard J, Fruzetti F, et al: Implications of smoking and oral contraceptive use. ARHP Clin Proc March: 1-11, 1996.
48. Mishell DR Jr, Carr BR, Comp PC, et al: Estrogen doses of oral contraceptives: what are the choices? Dialogues Contracept 4(8):1-12, 1996.
49. Fruzzetti F, Ricci C, Fioretti P: Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 49:579-592, 1994.
50. Basdevant A, Conard J, Pelissier C, et al: Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 μg to 20 μg in oral contraceptives containing desogestrel. Contraception 48:193-202, 1993.
51. Rosenberg MJ, Waugh MS, Stevens CM: Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 174:628-632, 1996.
52. Akerlund M, Rode A, Westergaard J: Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol. Br J Obstet Gynaecol 100:832-838, 1993.